Creating and providing pharmaceuticals that meet the needs of patients and healthcare professionals, and maximising corporate value
First written in FY2019. 3 of 4 entries say "Restated". Latest entry: FY2024-Q2.
3 other companies' latest entry also says "Restated".
- FY2024-Q2RestatedAnnual report
「The company established its 2031 Vision: “To remain a company that contributes to extending healthy life expectancy by rapidly creating and providing breakthrough new drugs” and “To be a global drug-discovery company focused on the dermatology and orthopaedics fields.”」
The direction of corporate value creation based on the 2031 Vision, including the provision of useful pharmaceuticals to patients and healthcare professionals, has been reaffirmed. - FY2022RestatedAnnual report
「① We strive to create and provide useful pharmaceuticals that meet the needs of patients and healthcare professionals.」
The company continues to pursue the creation and provision of pharmaceuticals that meet the needs of patients and healthcare professionals as its basic policy. - FY2021RestatedAnnual report
「① We strive to create and provide useful pharmaceuticals that meet the needs of patients and healthcare professionals.」
The company continues to pursue the creation and provision of pharmaceuticals that meet the needs of patients and healthcare professionals, and the maximisation of corporate value, as its basic policy. - FY2019First statedAnnual report
「We strive to create and provide useful pharmaceuticals that meet the needs of patients and healthcare professionals.」
The company has identified improving patients' quality of life as its corporate philosophy, and has set out the creation and provision of pharmaceuticals, social responsibility and high ethical standards, and being a company its employees can take pride in as its basic policies.